Anbio Biotechnology (NNNN) Liabilities and Shareholders Equity (2023 - 2025)

Anbio Biotechnology's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $30.2 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 59.83% year-over-year to $30.2 million; the TTM figure through Dec 2025 stood at $27680.7 billion (changed N/A YoY), while the FY2025 annual figure was $30.2 million, up 59.83% from the prior year.
• Liabilities and Shareholders Equity was $30.2 million for Q4 2025 at Anbio Biotechnology, down from $27680.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $27680.6 billion in Q2 2025 to a low of $15.8 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $6920.2 billion across 3 years, with a median of $24.6 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity climbed 19.67% in 2024, then soared 59.83% in 2025.
• A 3-year view of Liabilities and Shareholders Equity shows it stood at $15.8 million in 2023, then advanced by 19.67% to $18.9 million in 2024, then jumped by 59.83% to $30.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $30.2 million (Q4 2025), $27680.6 billion (Q2 2025), and $18.9 million (Q4 2024), per Business Quant data.